Watch CALC. Know when insiders buy.
One email the day a filing lands. Free.
CALC
CalciMedica, Inc.
2.30
+0.28 +13.61%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $78.4MP/E —DIV YIELD —FCF YIELD -24.40%REV TTM —NET INCOME −$21.2MNET CASH —52W 2.00 – 33.70SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4M | −$7.7M | — | -0.45 | −$4.6M | $0 | −$4.6M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$5.6M | $5M | — | 0.30 | −$4.9M | $0 | −$4.9M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.4M | −$10.8M | — | -0.69 | −$4.9M | $6K | −$4.9M | Mar 3 |
| Q3 2025 · Sep 30 | — | — | — | −$5.6M | −$7.8M | — | -0.52 | −$4.8M | $8K | −$4.8M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$6.6M | −$6M | — | -0.40 | −$6.7M | $5K | −$6.7M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$6.5M | −$5M | −3978.5% | -0.36 | −$4.9M | $9K | −$4.9M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.2M | −$4.3M | — | -0.34 | −$5M | $2K | −$5M | Mar 3 |
| Q3 2024 · Sep 30 | — | — | — | −$5.7M | −$5.6M | — | -0.50 | −$4.7M | $6K | −$4.7M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$6.5M | −$4M | — | -0.36 | −$6.8M | $0 | −$6.8M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$5.8M | $130K | — | 0.01 | −$4.7M | $0 | −$4.7M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$4.3M | −$4.1M | — | -0.23 | −$3.6M | $0 | −$3.6M | Mar 3 |
| Q3 2023 · Sep 30 | — | — | — | −$4.8M | −$4.6M | — | -0.82 | −$4.6M | $0 | −$4.6M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$23.1M | −$29.6M | — | -1.97 | −$21.2M | $28K | −$21.2M | — | — |
| FY2024 · to Dec 31 | — | — | −$24.2M | −$13.7M | — | -1.22 | −$21.1M | $8K | −$21.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$38.1M | −$34.4M | — | -7.66 | −$25.7M | $78K | −$25.8M | — | — |
| FY2022 · to Dec 31 | — | — | −$14.2M | −$7.8M | — | -111.16 | −$11.8M | $4K | −$11.8M | — | — |
| FY2021 · to Dec 31 | — | — | −$35.9M | −$35.8M | — | -1.69 | −$31.5M | $488K | −$32M | — | — |
| FY2020 · to Dec 31 | — | — | −$29.8M | −$27.5M | — | -5.25 | −$32.1M | $1M | −$33.1M | — | — |
Every number comes from CalciMedica, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.